Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

Devices, methods and compositions for treating cardiovascular disorders are configured for sustained-release of leptin antagonist into a blood vessel in order to downregulate an expression or activity of leptin in a cardiovascular tissue that is affected by a disorder.

Fibrous structures, for example sanitary tissue products, such as toilet tissue, containing one or more sensates, more particularly one or more TRPM8 receptor triggering agents, a sensate composition, for example surface softening composition, comprising one or more TRPM8 receptor triggering agents, and methods for making same are provided.

A method for obtaining epithelial organoids is provided. In one embodiment, the method comprises culturing one or more epithelial ducts, epithelial duct fragments and/or epithelial stem cells isolated therefrom in contact with an extracellular matrix in the presence of a basal medium, wherein the medium is free of FGF and/or nicotinamide. Organoids obtained by the methods described herein, and uses thereof, are also provided.

Compositions and related kits and methods for treating a target site of a patient are described herein. The composition may include a hemostatic agent and a pH agent, for example. Methods of treatment include delivering and applying the hemostatic agent and the pH agent to a gastrointestinal system of a patient via a medical device to reduce bleeding of tissue in the gastrointestinal system.

Disclosed herein are compositions and methods useful for manufacturing SC-? cell, and isolated populations of SC-? cells for use in various applications, such as cell therapy.

Provided herein are novel hyaluronic acid-based materials for in-situ gelation in wounds and other contexts, which materials are biocompatible and which have favorable gelation kinetics. The resulting hydrogels have desirable rheological properties. The invention encompasses novel reagents for forming crosslinked hyaluronic acid hydrogels, with favorable kinetics for medical applications and having desirable and tunable physical properties. Also presented herein are methods of using the novel materials disclosed herein in wound care and other medical contexts.

Compositions and methods are contemplated for treatment of a wound, and especially a sterile or TLR/NOD ligand-poor wound in which contemporaneous administration of a Ca.sup.2+-flux agonist (CFA) and a pattern recognition receptor (PRR) ligand improves wound healing.

The present disclosure describes compositions and methods to promote wound healing. The compositions and methods include an interleukin-1 beta (IL-1B) receptor antagonist (IL-1Ra), such as anakinra.

Compositions and methods are contemplated for treatment of a wound, and especially a sterile or TLR/NOD ligand-poor wound in which contemporaneous administration of a Ca.sup.2+-flux agonist (CFA) and a pattern recognition receptor (PRR) ligand improves wound healing.